Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 3Thoracic 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 40Triple Negative Breast Neoplasms 34Carcinoma, Non-Small-Cell Lung 28Melanoma 18Ovarian Neoplasms 16Carcinoma, Renal Cell 16Neoplasm Metastasis 13Pancreatic Neoplasms 12Carcinoma, Transitional Cell 12Colorectal Neoplasms 11Stomach Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Neoplasms 9Uterine Cervical Neoplasms 7Lung Neoplasms 7Head and Neck Neoplasms 7Endometrial Neoplasms 7Carcinoma, Merkel Cell 7Carcinoma, Hepatocellular 7Small Cell Lung Carcinoma 6Prostatic Neoplasms 6Gastrointestinal Neoplasms 5Sarcoma 4Mesothelioma 4Urinary Bladder Neoplasms 3Lymphoma 3Hodgkin Disease 3Esophageal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Ovarian Epithelial 3

Interventions

poly ICLC 1pembrolizumab 1enzalutamide 1durvalumab 1atezolizumab 1advexin 1Nivolumab 1High-Intensity Focused Ultrasound Ablation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Nivolumab × Breast × Clear all
NCT03544723 2020-06-09

Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

MultiVir, Inc.

Phase 2 Unknown
40 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicLymphoidThoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Hodgkin Disease, Liver Neoplasms, Lymphoma, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Neoplasms, Squamous Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡